Vistagen Therapeutics (VTGN) Tax Provisions (2011 - 2026)

Vistagen Therapeutics (VTGN) posted Tax Provisions of $7000.0 for Q1 2026, little changed sequentially from $7000.0 in Q3 2024.

Vistagen Therapeutics (VTGN) Tax Provisions (2011 - 2026) Analysis & Trends

Vistagen Therapeutics has reported Tax Provisions for 14 years, with the latest figure at $7000.0 in Q1 2026.

Quarterly Tax Provisions changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7000.0 (changed 0.0% YoY) and the FY2026 annual result came in at $7000.0, changed 0.0% from the prior year.
Tax Provisions was little changed at $7000.0 in Q1 2026 per VTGN's latest filing, from $7000.0 in the prior quarter.
Over five years, Tax Provisions peaked at $7000.0 in Q3 2024 and troughed at $1000.0 in Q1 2023.
A 4-year average of $4083.3 and a median of $4250.0 in 2022 frame the typical range for Tax Provisions.
The sharpest annual moves came in 2022 and 2023: Tax Provisions surged 83.33% in 2022, then tumbled 45.45% in 2023.
Over 4 years, Tax Provisions stood at $5500.0 in 2022, then sank by 45.45% to $3000.0 in 2023, then soared by 133.33% to $7000.0 in 2024, then changed by 0.0% to $7000.0 in 2026.
According to Business Quant data, Tax Provisions over the past three periods registered $7000.0, $7000.0, and $1000.0 for Q1 2026, Q3 2024, and Q1 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Vistagen Therapeutics	10.49 Mn	10.49 Mn	-	-

Download Data